For years, the NAD+ precursor debate has been framed as NMN versus NR — as if the two molecules competed on equal footing. The pharmacokinetic data tell a different story. Once you account for first-pass hepatic metabolism, intestinal conversion, the controversial Slc12a8 transporter, and the simple fact that NAD+ itself does not cross plasma membranes intact, the question stops being “which precursor is best?” and becomes “which tissue are you trying to reach, and by what route?” That distinction reframes nearly every clinical decision in the NAD+ space.
What Are NMN, NR, and NAD+?
Nicotinamide adenine dinucleotide (NAD+) is a redox coenzyme essential for mitochondrial respiration, sirtuin deacetylation, and PARP-mediated DNA repair. Tissue NAD+ declines roughly 10–25% per decade in humans, and restoring it has become a central goal of metabolic and longevity medicine.[1]
Because NAD+ itself is a large, charged dinucleotide that does not efficiently cross plasma membranes, supplementation strategies almost universally rely on precursors. The two leading oral candidates are nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR). NMN is a phosphorylated nucleotide; NR is the dephosphorylated riboside. Both feed the salvage pathway, but they enter cells through different routes — and that difference dictates tissue distribution.[2]
How Each Precursor Reaches Tissues
NR Pathway: Oral NR is absorbed in the small intestine and rapidly phosphorylated by nicotinamide riboside kinases (NRK1 and NRK2) to NMN, then converted to NAD+ by NMNAT enzymes. However, a substantial fraction of oral NR is hydrolyzed to nicotinamide (NAM) by intestinal and hepatic enzymes before reaching peripheral tissues. The liver acts as a major sink, and what reaches skeletal muscle or brain often arrives as NAM rather than intact NR.[2]
NMN Pathway — Direct Transport: In 2019, Yoshino and colleagues identified Slc12a8 as a putative direct NMN transporter in the murine small intestine, suggesting NMN could be absorbed intact without dephosphorylation to NR.[3] This finding was contested by the Brenner laboratory, which argued NMN must first be dephosphorylated extracellularly to NR before cellular uptake.[4] The literature has not fully resolved this debate, but the practical consequence is that oral NMN and oral NR likely converge on similar systemic NAD+ kinetics — both significantly attenuated by first-pass metabolism.
Direct NAD+ — Parenteral Only: Intact NAD+ administered intravenously bypasses the gut and liver entirely. However, NAD+ does not cross the plasma membrane intact in most cell types; it is hydrolyzed extracellularly by CD38 and CD73 to NMN and then NR before cellular uptake. Subcutaneous NAD+ shows similar extracellular processing but slower absorption kinetics. The advantage of parenteral NAD+ is not that NAD+ enters cells whole, but that it delivers a high bolus of precursor downstream of intestinal and hepatic clearance.[5]
Pharmacokinetic Evidence in Humans
Oral NR Kinetics: Trammell and colleagues conducted the first human pharmacokinetic study of NR, demonstrating dose-dependent increases in whole-blood NAD+ over 24 hours after single oral doses of 100, 300, and 1000 mg. Peak NAD+ elevation occurred at 8 hours, with NAM as the dominant circulating metabolite — confirming substantial first-pass conversion.[2]
Oral NMN Kinetics: Irie and colleagues conducted the first human safety and pharmacokinetic study of oral NMN at 100, 250, and 500 mg in healthy men. Plasma NMN itself did not rise appreciably; instead, downstream metabolites (NAM, methylnicotinamide) increased dose-dependently. This pattern is consistent with rapid intestinal or hepatic conversion rather than intact NMN reaching the systemic circulation.[6]
Tissue Distribution Limits: A consistent finding across rodent and human studies is that whole-blood and peripheral blood mononuclear cell (PBMC) NAD+ rises reliably with oral precursor dosing, but tissue-specific uplift in skeletal muscle and brain is far more modest. Martens and colleagues showed that oral NR at 1000 mg/day for 6 weeks raised PBMC NAD+ by ~60% in middle-aged adults but produced no detectable change in resting muscle NAD+ on biopsy.[7]
Why Route Determines Tissue Outcome
The Liver as a Bottleneck: Both oral NMN and oral NR are heavily extracted by the liver on first pass. Hepatocytes express high levels of NRK1 and NMNAT, and the liver is metabolically positioned to capture and recycle nicotinamide-containing molecules. This is therapeutically useful for hepatic NAD+ but limits delivery to muscle, brain, and adipose tissue.
Sublingual and Intranasal Routes: Sublingual NMN bypasses portal circulation, theoretically improving systemic exposure, though controlled human pharmacokinetic data remain limited. Intranasal NAD+ has been proposed as a route to the central nervous system via olfactory and trigeminal pathways, but rigorous human PK studies are lacking.
Subcutaneous and IV NAD+: Parenteral NAD+ produces the largest absolute rise in circulating precursor pools and is the only route that meaningfully bypasses both intestinal and hepatic first-pass effects. The trade-off is invasiveness, cost, and the absence of large randomized trials documenting long-term tissue-level outcomes versus oral precursors.
Clinical Evidence by Indication
Cardiometabolic: Martens et al. demonstrated that oral NR at 1000 mg/day for 6 weeks reduced systolic blood pressure and aortic stiffness in adults with elevated blood pressure, with PBMC NAD+ as the surrogate biomarker.[7] The vascular endothelium appears responsive to circulating precursor pools that oral dosing can reach.
Skeletal Muscle: Despite strong preclinical rationale, human trials of oral NR and NMN have shown inconsistent effects on muscle NAD+ and function. The Martens trial showed no muscle NAD+ rise; later studies using oral NMN in older adults have shown modest improvements in walking speed and grip strength, but tissue NAD+ measurements remain sparse.[6]
Central Nervous System: The blood-brain barrier is a substantial obstacle for both NMN and NR. Whether either precursor meaningfully raises brain NAD+ in humans at oral doses is unresolved. This is where alternative routes — intranasal, subcutaneous — are theoretically attractive but evidentially thin.
Safety Profile
Across human trials, oral NR up to 2000 mg/day and oral NMN up to 1250 mg/day have been well tolerated, with adverse events similar to placebo. The most common side effects are mild gastrointestinal symptoms and transient flushing.[2][6] Long-term safety data beyond 12 months remain limited for both compounds. Parenteral NAD+ has a longer clinical history in addiction medicine but lacks rigorous controlled safety trials at modern longevity-oriented doses.
A theoretical concern with chronic high-dose precursor loading is methylation stress: NAM clearance via NNMT consumes S-adenosylmethionine, potentially affecting one-carbon metabolism. Clinically meaningful methylation depletion has not been demonstrated in published trials, but it argues for moderation in dosing rather than maximalism.
NMN vs NR vs Direct NAD+: Practical Synthesis
For cardiovascular and metabolic targets: Oral NR and NMN both raise circulating NAD+ pools sufficient to engage vascular endothelium and liver. The choice between them is largely empirical; head-to-head pharmacokinetic differences in humans appear modest.
For skeletal muscle and brain: Oral precursors face significant tissue-distribution limits. Higher doses, longer durations, or alternative routes may be required, and biomarker monitoring should not assume that PBMC NAD+ reflects tissue NAD+.
For maximal systemic exposure: Parenteral NAD+ remains the only route that bypasses first-pass losses, though the evidence base for superior clinical outcomes versus oral precursors is not yet established.
The most useful reframing for clinicians: NMN, NR, and NAD+ are not interchangeable products competing on potency. They are different pharmacokinetic strategies for raising NAD+ in different tissue compartments. Matching the route to the target tissue — rather than chasing the highest oral dose — is the more defensible clinical approach.
References
- Covarrubias AJ, et al. “NAD+ metabolism and its roles in cellular processes during ageing.” Nature Reviews Molecular Cell Biology. 2021;22(2):119-141.
- Trammell SA, et al. “Nicotinamide riboside is uniquely and orally bioavailable in mice and humans.” Nature Communications. 2016;7:12948.
- Grozio A, et al. “Slc12a8 is a nicotinamide mononucleotide transporter.” Nature Metabolism. 2019;1(1):47-57.
- Schmidt MS, Brenner C. “Absence of evidence that Slc12a8 encodes a nicotinamide mononucleotide transporter.” Nature Metabolism. 2019;1(7):660-661.
- Rajman L, et al. “Therapeutic potential of NAD-boosting molecules: the in vivo evidence.” Cell Metabolism. 2018;27(3):529-547.
- Irie J, et al. “Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men.” Endocrine Journal. 2020;67(2):153-160.
- Martens CR, et al. “Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults.” Nature Communications. 2018;9:1286.
